InflaRx Q3 2026 Earnings Date & Estimates

InflaRx (NASDAQ:IFRX) (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for severe and life-threatening inflammatory diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune system that can contribute to tissue damage when excessively activated.

InflaRx’s lead product is vilobelimab, a monoclonal antibody designed to selectively block the complement protein C5a while preserving other components of the immune response. In the United States, vilobelimab is marketed under the brand name Gohibic and received accelerated approval from the U.S. Food and Drug Administration in 2023 for certain critically ill adults with COVID-19 who require invasive mechanical ventilation or extracorporeal membrane oxygenation.

The company has also studied vilobelimab in additional inflammatory and autoimmune conditions, including hidradenitis suppurativa, ANCA-associated vasculitis and pyoderma gangrenosum. InflaRx’s operations and clinical development activities have an international focus, with research and potential commercial activities spanning the United States, Europe and other regions. Niels C. Riedemann, M.D., a co-founder of InflaRx, serves as the company’s chief executive officer.